Surgery supported by orthopaedic robots has increased significantly over the past years such as knee reconstruction, which is is one of the fastest-growing procedures. According to GlobalData analysis, there are approximately three million knee reconstruction surgeries worldwide annually. In 2020, around 11% of knee reconstruction surgeries were completed with the support of robotic assistance. It is expected the number of robotic-assisted knee reconstruction surgeries will reach approximately 700,000 globally by 2030, with a Compound Annual Growth Rate (CAGR) of 8% from 2021 to 2030.

In comparison with a conventional procedure, robotic total knee surgery improves surgeons’ consistency and accuracy to control implant positioning, ligament balance and limb alignment, leading to decreased postoperative pain, a shorter stay in the hospital and better knee flexion on discharge. Potential disadvantages include a learning curve, longer operation time, increased radiation exposure, and financial costs. Additionally, there is little evidence suggesting improved clinical outcomes and reduced revision rates in the long term. Despite the drawbacks, most joint reconstruction surgeons support the usage of orthopaedic robots to improve precision and short-term patient outcomes in knee reconstruction surgeries. Therefore, robotic-assisted knee procedures have experienced rapid growth in surgical application with an increased number of different robotic platforms.

The most popular surgical robots for knee reconstruction include Stryker Mako, Zimmer Biomet ROSA Knee, Smith & Nephew CORI and newly approved Johnson & Johnson VELYS, controlling over 95% of the knee robots market in the US. All the robots are compatible only with partial and/or total knee implants from the same manufacturer. Therefore, more installed bases of knee robots mean more potential shares in the knee implants market. It can be expected the competition among major players will be more intense by racing in both capital equipment and consumable markets. According to GlobalData analysis, prior to the Covid-19 pandemic, the knee reconstruction market was valued at $8.4bn globally, with Zimmer Biomet, the clear leader, representing approximately a third of the global market, followed by Johnson & Johnson, Stryker and Smith & Nephew. The remainder of the market is occupied by several small-to-mid-cap orthopaedic companies, with less than 20% of the market. To date, none of the smaller players has yet launched their robotic platforms due to technological and financial challenges. GlobalData expects the leading positions of the four orthopaedic giants will be strengthened while robotic-assisted knee procedures gain popularity.